September 2, 2026
MIRA Pharmaceuticals completed short-term toxicology studies for MIRA-55 in rats and dogs, keeping its timeline for an IND filing in early 2027 on track but leaving investors to weigh two years of cash burn against a slim chance of approval.
What happened
MIRA Pharmaceuticals announced results from 7-day dose-range finding toxicology studies of MIRA-55 in rats and dogs. The company reiterated its target to submit an Investigational New Drug application to the FDA in the first quarter of 2027. Despite the news, MIRA shares slipped 1 percent on the day, against a broader market that climbed.
Why it matters
A completed tox study is a required step on the path to human trials. For a small preclinical company like MIRA, hitting these interim milestones without a safety surprise keeps the regulatory story alive. Because an IND is nearly two years away, the stock price reflects a discounted bet that the asset ever generates revenue, rather than a re-rating on today's data. The modest move suggests the market had already priced in a clean result, so the update did little to change the odds of eventual approval.
The case against
The drug is still years from generating a dollar of revenue, and the vast majority of neurology assets fail in the clinic. MIRA-55 hasn't yet proven it can cross the blood-brain barrier effectively or change a disease endpoint in humans, so completing a one-week animal study is a tiny step in a long, high-risk process.
What settles it
The full data from these toxicology studies, including the margin between the effective dose and the dose that caused adverse effects, which will determine how much room the program has in first-in-human trials.